These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12903845)

  • 21. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer prevention with selective estrogen receptor modulators: a perspective.
    Pritchard KI
    Ann N Y Acad Sci; 2001 Dec; 949():89-98. PubMed ID: 11795385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of tamoxifen.
    Robert NJ
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):15-20. PubMed ID: 9065922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century.
    Fisher B
    Eur J Cancer; 1999 Dec; 35(14):1963-73. PubMed ID: 10711239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen's clinical applications: old and new.
    Buzdar AU
    Arch Fam Med; 2000; 9(9):906-12. PubMed ID: 11031399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of breast cancer in high-risk women.
    Kardinal CG; Veith R
    J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final results from the NSABP Breast Cancer Prevention Trial.
    Oncology (Williston Park); 2005 Dec; 19(14):1800. PubMed ID: 16506633
    [No Abstract]   [Full Text] [Related]  

  • 33. [Chemoprevention of breast cancer: a hope justified?].
    Buser K; Delaloye JF
    Rev Med Suisse Romande; 2000 Jun; 120(6):511-3. PubMed ID: 11014095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1).
    Wolmark N; Dunn BK
    Ann N Y Acad Sci; 2001 Dec; 949():99-108. PubMed ID: 11795386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of tamoxifen use: An update for the surgical oncologist.
    Heerdt AS; Borgen PI
    J Surg Oncol; 1999 Sep; 72(1):42-9. PubMed ID: 10477879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.
    Reis SE; Costantino JP; Wickerham DL; Tan-Chiu E; Wang J; Kavanah M
    J Natl Cancer Inst; 2001 Jan; 93(1):16-21. PubMed ID: 11136837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Cuzick J; Forbes JF; Howell A
    J Natl Cancer Inst; 2006 May; 98(9):643; author reply 643-4. PubMed ID: 16670391
    [No Abstract]   [Full Text] [Related]  

  • 39. Tamoxifen's impact on the management of breast cancer: the oncologist's perspective.
    Glick JH; Aviles VM; Wallmark J
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):49-54. PubMed ID: 9065928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
    Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
    Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.